Twenty patient questions about GVHD: treatment, tapering, care in China, and follow-up

Graft-versus-host disease brings together transplant history, immune treatment, and problems affecting several organs. Different statements can seem contradictory when their clinical settings are missing. These answers place common questions in context, using information checked in September 2026. They are intended to support discussion with the treating team; individual decisions still require current findings, previous treatment history, and locally available services.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

GVHD involves immune cells originating from the donor causing injury to the recipient's tissues. That direction differs from the usual idea of the recipient rejecting a graft. It occurs particularly in the setting of allogeneic hematopoietic cell transplantation and can involve skin, the gastrointestinal tract, liver, and other organs in chronic disease. Understanding the distinction helps avoid the misconception that treatment should simply remove unsuitable donated cells. Symptoms after transplant still need assessment in context; discomfort alone cannot establish the diagnosis.[1]
The exact product matters. China's conditional amimestrocel approval concerns patients aged at least 14 years with steroid-treatment-failed acute GVHD predominantly affecting the gastrointestinal tract. US Ryoncil is a different product for pediatric steroid-refractory acute GVHD. Cell source, preparation, and supporting studies are not interchangeable. One authorization cannot justify equivalent claims for an unspecified preparation, chronic lung manifestations, or every age group. Cellular treatment also requires its own administration and safety monitoring; its name is not evidence that adverse effects are absent.[11,12]
Continue regimen-specific blood and biochemical monitoring, assessment of affected organs, infection prevention, vaccination planning, and original-disease follow-up. Identify the home prescriber, who reviews results, and which symptoms require local emergency care. Eye and oral care, rehabilitation, and children's growth and school needs may also remain relevant. Long-term transplant recommendations support individualized surveillance; symptom improvement or stopping systemic medicines does not end every follow-up requirement. Before leaving China, put the next task and responsible clinician in writing.[20]

Quick answer

Full guide

1. Is GVHD the body rejecting the donated stem cells?

GVHD involves immune cells originating from the donor causing injury to the recipient's tissues. That direction differs from the usual idea of the recipient rejecting a graft. It occurs particularly in the setting of allogeneic hematopoietic cell transplantation and can involve skin, the gastrointestinal tract, liver, and other organs in chronic disease. Understanding the distinction helps avoid the misconception that treatment should simply remove unsuitable donated cells. Symptoms after transplant still need assessment in context; discomfort alone cannot establish the diagnosis.[1]

2. Can relatives catch GVHD from the patient?

GVHD itself is not an infection transmitted between people. The household infection concern is that the patient's immune status and treatment may increase susceptibility to pathogens. Follow the transplant team's advice on hand hygiene, contact with people who are unwell, and practical home care. The diagnosis does not require withdrawing ordinary emotional support or assuming that family members will contract GVHD. If someone in the household develops an infection, tell the team so that contact and prevention can be considered appropriately.[1,2]

3. Does disease after day 100 have to be chronic GVHD?

No. Acute GVHD manifestations can occur after day 100, and chronic GVHD depends on characteristic clinical features and appropriate confirmation, not only a date. Some patients have chronic findings together with acute-type manifestations. The timeline remains important, but does not replace the clinical pattern. A new rash or diarrhea several months after transplantation should not be dismissed because the patient is supposedly beyond the acute period, or automatically labeled a chronic GVHD recurrence without assessment.[3]

4. Can one blood test confirm GVHD?

Diagnosis usually requires clinical assessment, organ-related investigations, and consideration of similar conditions. Chronic GVHD criteria specify characteristic manifestations, and some situations need tissue or other supporting evidence. Abnormal liver enzymes, diarrhea, and dry eyes can each have more than one explanation. Bring complete records so that the team can identify the unresolved question and select useful tests. Buying a single advertised GVHD screening test is not a substitute for assessment and should not become the basis for independently starting immune-suppressive treatment.[3,4]

5. Does everyone need another biopsy?

No. The value of biopsy depends on the affected site, diagnostic uncertainty, and whether the result could change care. A new sample is not automatically needed whenever symptoms fluctuate. Prior immune treatment and sampling location can affect pathological findings, so the report needs clinical interpretation. Submit the complete previous result and ask whether review of slides or new sampling is indicated. A nonspecific tissue result should not be interpreted in isolation as proof that GVHD has been excluded.[5]

6. Why can GVHD occur with excellent donor chimerism?

Chimerism describes whether the tested cells are derived from donor or recipient. It does not directly determine whether immune cells are injuring a particular organ. Complete donor chimerism therefore does not prove absence of GVHD or guarantee that the original disease can never recur. Clinicians use it for relevant transplant and disease-monitoring questions while assessing GVHD through other findings. When submitting results to a new hospital, preserve the date and cell population tested rather than summarizing the result only as a successful transplant.[6]

7. Can GVHD be cured?

Some patients achieve sustained control and eventually stop systemic treatment; others need continuing management and may retain organ damage. Symptom improvement, a partial response, and long-term freedom from medication are different outcomes. Studies of durable treatment discontinuation follow patients for extended periods, so several symptom-free weeks cannot establish permanent resolution. Useful personal goals include controlling dangerous organ progression, reducing steroid burden, and improving eating or movement while the opportunity for treatment reduction is reassessed. An individual cure promise cannot be justified at the first consultation.[7]

8. Should treatment begin with the newest or most expensive drug?

Treatment intensity follows disease form, severity, and organ involvement. The 2026 ASTCT recommendations retain corticosteroids as the basis of initial systemic treatment for acute GVHD, with subsequent choices guided by response. Limited local symptoms and disease requiring systemic treatment should not be treated as identical situations. Novelty and price do not establish suitability for first-line use. Ask which risk the current treatment addresses, when benefit will be reviewed, and what would prompt another approach rather than arranging options by cost.[8]

9. Is ruxolitinib suitable for every GVHD patient?

It has defined indications and monitoring requirements. The 2026 ASTCT recommendations identify it as standard second-line treatment for steroid-refractory acute GVHD, but infection, blood counts, organ function, and interactions still matter. Chinese GVHD indications also contain age and previous-response conditions. A formulation newly available overseas does not establish availability in China, and the administration schedule must match the actual prescribed product. Patients should not copy a dose from another disease setting or adjust treatment independently from information found online.[8,9]

10. Are Chinese and US belumosudil eligibility rules identical?

They should not be assumed to be identical. The Chinese label revised in 2026 addresses patients aged 12 years and older with chronic GVHD responding inadequately to corticosteroids or other systemic treatment. That wording should not be replaced with the US requirement for at least two failed systemic lines. Selection also requires review of liver function, accompanying medicines, and the actual prescription. Authorization defines an indication, not stock in every hospital or the same reimbursement entitlement for all international patients.[10]

11. Is stem cell treatment for GVHD now universally established?

The exact product matters. China's conditional amimestrocel approval concerns patients aged at least 14 years with steroid-treatment-failed acute GVHD predominantly affecting the gastrointestinal tract. US Ryoncil is a different product for pediatric steroid-refractory acute GVHD. Cell source, preparation, and supporting studies are not interchangeable. One authorization cannot justify equivalent claims for an unspecified preparation, chronic lung manifestations, or every age group. Cellular treatment also requires its own administration and safety monitoring; its name is not evidence that adverse effects are absent.[11,12]

12. Can the 2026 TREGZI approval treat GVHD that has already developed?

The US approval concerns a defined matched-donor transplantation pathway after myeloablative preparation in adults with hematologic malignancies. Its aims include hematopoietic and immune reconstitution and improvement in chronic-GVHD-free survival. It should not be interpreted as proof that an extra infusion reverses established GVHD. The relevant composite endpoint is also not a leukemia cure rate. Ask whether the development relates to the current clinical stage; it does not independently justify repeat transplantation or establish Chinese access to the product.[13]

13. Is photopheresis a form of whole-body radiotherapy?

Extracorporeal photopheresis, or ECP, treats a portion of collected blood cells outside the body using a photosensitizing medicine and ultraviolet light before reinfusion. It is not ordinary cancer radiotherapy and does not replace all the patient's blood. Vascular access, anticoagulation, repeated visits, and light-protection instructions are part of the procedure. Suitability depends on the clinical situation. One completed session is not a cure; confirm the planned schedule, reassessment criteria, and whether treatment can continue after returning home.[14]

14. Can fever during treatment be watched at home first?

After allogeneic transplantation, fever of 38°C or higher should prompt immediate contact with the medical team and timely assessment as directed. Severe breathlessness, altered consciousness, collapse, or significant bleeding requires local emergency care. Immune suppression can make infection less typical, so danger cannot be judged only from whether fever is high. Do not automatically label fever after an infusion harmless or rely on temperature reduction alone. Tell the evaluating clinician about transplantation, GVHD, and every active medicine.[2]

15. Can corticosteroids be stopped when symptoms improve?

Not independently. Prolonged corticosteroid treatment suppresses the body's own steroid response, and sudden withdrawal can be dangerous. GVHD may also become active during reduction. Obtain an individual taper with review arrangements and contact instructions for infection, surgery, or inability to take oral medication. New fatigue, diarrhea, or other symptoms can have several explanations and should not automatically trigger a return to the highest previous dose. Reducing corticosteroids, stopping one medicine, and ending all systemic treatment are separate steps.[15]

16. How much money should be budgeted for treatment in China?

Request an estimate for the actual clinical phase rather than applying a transplant package price to GVHD. Peking University People's Hospital's international page lists consultations at RMB 1,000–4,000 per visit and ward charges at RMB 1,000–1,500 per day, with additional examinations and treatment discussed separately. These are limited service examples, not complete-care prices. Medicines, infection management, nutrition, specialist assessments, and length of stay can change the total. A reliable personal budget requires an itemized hospital quotation.[16]

17. Should hospitals be selected mainly by transplant numbers?

Transplant experience is relevant, but current GVHD care also requires complication management, organ expertise, and continuing follow-up. Eye and oral problems may need specialist examinations, while pulmonary disease needs lung-function assessment and other investigation. A transplant volume cannot substitute for these services. Confirm who directs systemic treatment, integrates other specialties, accepts patients transplanted elsewhere, and can deliver the proposed intervention. Historical success rates and research announcements cannot establish an individual's outcome or current bed availability.[17,18]

18. When can travel to China or the return journey be arranged?

The current team should assess stability, immune treatment, infection, cardiopulmonary status, and practical support. A transplant anniversary is not universal flight clearance, and discharge does not automatically mean readiness for a long flight. Confirm the receiving service, necessary support, medication supply, and journey arrangements. CDC guidance emphasizes individualized prevention and contingency planning for immunocompromised travelers. If the condition is worsening, obtain local medical care first, then let clinicians determine whether travel or a medically coordinated transfer is appropriate.[19]

19. Which records are most useful for a first consultation?

Prioritize the transplant summary, GVHD timeline, dose changes and stopping reasons for previous treatments, current prescription, and serial results from the main affected organs. Bring full lung-function reports, pathology wording with specimen dates, and dated photographs labeled by site. Include original-disease status, significant infections, and allergies in an index. The purpose is to support diagnosis and response assessment, not to make patients undergo additional biopsies or other invasive investigations merely to complete a standard document package.[3,5,18]

20. What follow-up continues after returning home?

Continue regimen-specific blood and biochemical monitoring, assessment of affected organs, infection prevention, vaccination planning, and original-disease follow-up. Identify the home prescriber, who reviews results, and which symptoms require local emergency care. Eye and oral care, rehabilitation, and children's growth and school needs may also remain relevant. Long-term transplant recommendations support individualized surveillance; symptom improvement or stopping systemic medicines does not end every follow-up requirement. Before leaving China, put the next task and responsible clinician in writing.[20]

References

MSK. GVHD overview: https://www.mskcc.org/cancer-care/types/graft-versus-host-disease-gvhd
MSK. Care after allogeneic transplant discharge: https://www.mskcc.org/cancer-care/patient-education/leaving-hospital-after-your-allogeneic-transplant
NIH. Chronic GVHD diagnosis and staging: https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
EBMT Handbook. Acute GVHD: https://www.ncbi.nlm.nih.gov/books/NBK608233/
NIH. Chronic GVHD pathology recommendations: https://pmc.ncbi.nlm.nih.gov/articles/PMC4359636/
EBMT Handbook. Chimerism: https://www.ncbi.nlm.nih.gov/books/NBK608246/
Chen and colleagues. Durable systemic-treatment discontinuation: https://haematologica.org/article/view/haematol.2021.279814
ASTCT. Acute GVHD treatment recommendations, 2026: https://pubmed.ncbi.nlm.nih.gov/42155643/
Novartis China. Ruxolitinib chronic GVHD indication: https://www.novartis.com.cn/news/jiekewei-linsuanluketinipianzhiliaomanxingyizhiwukangsuzhubingxinshiyingzhengzaihuahuopi
Sanofi China. Belumosudil prescribing information, 2026: https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/rezurock-cn-20260122.pdf
NMPA. Amimestrocel injection: https://english.nmpa.gov.cn/2025-06/11/c_1101502.htm
FDA. Ryoncil pediatric acute GVHD approval: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric
FDA. TREGZI approval: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched
MSK. Photopheresis questions: https://www.mskcc.org/cancer-care/patient-education/frequently-asked-questions-about-photopheresis
MSK. Prednisone information: https://www.mskcc.org/cancer-care/patient-education/medications/adult/prednisone
Peking University People's Hospital. International patient FAQ and charges: https://english.pkuph.cn/care/overview_g7yU_57.html
EBMT Handbook. Ocular and oral complications: https://www.ncbi.nlm.nih.gov/books/NBK608294/
NIH. Chronic GVHD response assessment: https://pmc.ncbi.nlm.nih.gov/articles/PMC4744804/
CDC Yellow Book 2026. Immunocompromised travelers: https://www.cdc.gov/yellow-book/hcp/travelers-with-additional-considerations/immunocompromised-travelers.html
International long-term transplant screening and prevention recommendations, 2023 update: https://pmc.ncbi.nlm.nih.gov/articles/PMC11181337/